ALFA Finder
Fri, 13 Nov
Natco Pharma
Natco delivered a solid performance with diversified growth in Brazil and South Africa, successfully offsetting the expected decline in Revlimid revenue.
Summary ready
Earnings calls
Natco Pharma concalls
Every Natco Pharma earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Natco delivered a solid performance with diversified growth in Brazil and South Africa, successfully offsetting the expected decline in Revlimid revenue.
Outlook
Management raised PAT guidance to ₹775-800 Cr for FY27; FY28 target is 10-15% top-line growth.
Earlier call summaries
All →
18:55 IST
NSE
Earnings Call
Natco Pharma Earnings Call Transcript: Key Takeaways
Natco reported a sharp revenue decline due to lower Revlimid contributions, masked by strong growth in Brazil and domestic segments.
14:53 IST
BSE
Earnings Call
Natco Pharma Earnings Call: Key Takeaways
Natco Pharma reported Q4 FY26 revenue of ₹816.9cr and PAT of ₹269cr. The company is diversifying into Brazil, Canada, and South Africa to counter Revlimid decline.
12:18 IST
BSE
Earnings Call
Natco Pharma Earnings Call: Key Takeaways
Natco Pharma faces a sharp transition as Revlimid-led super-profits decline, shifting focus to Brazil and Canada. Management guides for a significant 50% profit contraction in FY27 as it attempts to diversify earnings.
15:30 IST
NSE
Earnings Call
Natco Pharma Earnings Call: Key Takeaways
Natco Pharma reported FY26 revenue of INR 43,759 Mn and PAT of INR 14,185 Mn, driven by US generic launches and high export formulation contributions.
Natco Pharma Ltd: key numbers
- Share price
- ₹810.45
- Market cap
- ₹15,898 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 19.2×Sector 43.7×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.